Valthos, Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Valthos, Inc. - overview

Established

2024

Location

New York, NY, US

Primary Industry

Software

About

Based in the US, Valthos develops artificial intelligence-driven solutions for biodefense, focusing on enhancing public health security through innovative technologies. Valthos, Inc. is a biodefense firm founded in 2024 and headquartered in New York, US. The company specializes in developing systems to address biodefense challenges but has not reported any significant pivots in its business strategy.


The firm has secured USD 30. 00 mn in funding from investors such as Founders Fund, Lux Capital, and OpenAI in its Seed round on October 24, 2025, which marks its total amount raised to USD 30. 00 mn. Valthos specializes in advanced biodefense solutions, focusing on the development and deployment of innovative products aimed at enhancing public health security.


Their core offerings address various biodefense challenges, including pathogen detection, vaccine development, and rapid response systems for biological threats. These solutions are particularly relevant to government and military sectors, serving end users like public health agencies and emergency response teams across North America, Europe, and parts of Asia. Valthos generates revenue through a structured model emphasizing B2B transactions with government agencies and defense organizations. The company engages in contracts often involving multi-year agreements for its biodefense products and services, along with partnerships for co-development of tailored technologies.


Clients typically participate in both direct purchases and long-term subscription agreements, ensuring a continuous revenue stream as they rely on Valthos for essential biodefense capabilities. In October 2025, Valthos raised USD 30. 00 mn in Seed funding to exit stealth mode and develop AI-powered tools designed to detect and counter bioweapon threats. The company plans to expand its offerings into new markets, with targeted growth initiatives for the next few years that aim to enhance its presence in the biodefense sector.


The recent funding will support these efforts as Valthos accelerates the development of new products and seeks to establish a stronger foothold in the global market.


Current Investors

Founders Fund, Lux Capital, OpenAI

Primary Industry

Software

Sub Industries

Biotechnology, IT Security/Cybersecurity, Monitoring & Security Software, Analytics & Performance Software

Website

www.valthos.com

Verticals

Artificial Intelligence, Cloud Computing

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.